Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.42 |
| ▸ | WNT3A | P56704 | 3/20 | 0.39 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319563 | 0.88 | ABL1 (0.43) | HDAC1HDAC2DEGS1WNT3ACHRM3 | |
| SCHEMBL2317904 | 0.82 | DEGS1 (0.53) | HDAC1HDAC2DEGS1WNT3AABL1 | |
| SCHEMBL2320166 | 0.80 | RAB9A (0.48) | HDAC1HDAC2DEGS1ALDH1A1 | |
| SCHEMBL2317319 | 0.78 | DEGS1 (0.45) | HDAC1HDAC2DEGS1WNT3AALDH1A1 | |
| SCHEMBL2319777 | 0.73 | USP30 (0.47) | HDAC1HDAC2DEGS1 | |
| SCHEMBL2318673 | 0.72 | HDAC1 (0.45) | HDAC1HDAC2 | |
| SCHEMBL12283692 | 0.72 | USP30 (0.55) | HDAC1HDAC2DEGS1WNT3AABL1 | |
| SCHEMBL2315755 | 0.71 | USP30 (0.52) | HDAC1HDAC2DEGS1WNT3AABL1 | |
| SCHEMBL2317561 | 0.71 | MAPK8 (0.53) | HDAC1HDAC2WNT3A | |
| SCHEMBL2323355 | 0.71 | FFAR4 (0.46) | HDAC1HDAC2DEGS1WNT3AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | HDAC1 1924/4885HDAC2 1893/4885DEGS1 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.